Monopar Therapeutics Inc. (MNPR)
NASDAQ: MNPR · Real-Time Price · USD
72.00
-0.68 (-0.94%)
Nov 13, 2026, 4:00 PM EST - Market closed

Monopar Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
8.866.83.163.232.952.63
Research & Development
16.639.913.015.67.596.49
Operating Expenses
25.4916.716.168.8310.549.13
Operating Income
-25.49-16.7-16.16-8.83-10.54-9.13
Interest & Investment Income
4.862.990.40.430.020.02
Other Non Operating Income (Expenses)
0.03-0.17---
EBT Excluding Unusual Items
-20.6-13.72-15.59-8.4-10.52-9.1
Pretax Income
-20.6-13.72-15.59-8.4-10.52-9.1
Net Income
-20.6-13.72-15.59-8.4-10.52-9.1
Net Income to Common
-20.6-13.72-15.59-8.4-10.52-9.1
Net Income Growth
------
Shares Outstanding (Basic)
974332
Shares Outstanding (Diluted)
974332
Shares Change
31.37%95.53%37.09%8.70%1.97%13.82%
EPS (Basic)
-2.41-1.85-4.11-3.04-4.13-3.65
EPS (Diluted)
-2.41-1.85-4.11-3.04-4.13-3.65
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EBIT
-25.49-16.7-16.16-8.83-10.54-9.13
SEC Filings: 10-K · 10-Q